These are top 10 stocks traded on the Robinhood UK platform in July
Marshall Stanton, Senior Vice President of Clinical and Medical (TASE:BLWV) Affairs at Artivion, Inc. (NYSE:AORT), reported a sale of 1,603 shares of the company’s common stock on March 6, 2025. The medical device company, currently valued at approximately $990 million, has received a "GOOD" overall financial health rating according to InvestingPro analysis. The shares were sold at an average price of $24.8042, totaling approximately $39,761. This transaction was executed to cover tax withholding obligations related to the vesting of performance stock units, rather than as a discretionary sale. The stock, which currently trades near $23.50, has shown significant volatility, trading between $19.11 and $32.33 over the past 52 weeks. Following the transaction, Stanton holds 115,880 shares directly. Additionally, Stanton acquired 19,240 performance stock units at no cost, which are part of a grant issued in February 2024. Analysts maintain a strong buy consensus on Artivion, with price targets ranging from $30 to $35. For deeper insights into Artivion’s valuation and growth prospects, including 8 additional exclusive ProTips, visit InvestingPro.
In other recent news, Artivion Inc. reported its fourth-quarter 2024 revenue at $97.3 million, which fell short of the forecasted $100.82 million due to a cybersecurity incident that impacted sales by approximately $4.5 million. Despite this, the company achieved a 3% year-over-year revenue growth and an adjusted EBITDA of $17.6 million, surpassing expectations. Analysts at Stifel and Needham adjusted their price targets for Artivion to $30 and $32, respectively, while maintaining Buy ratings, reflecting concerns over the cybersecurity incident’s impact on future quarters.
JMP Securities, however, maintained its $33 price target and Market Outperform rating, expressing confidence in Artivion’s recovery. The cybersecurity breach caused an 8% decline in the tissue preservation division, but management indicated that operations have returned to normal levels. Artivion anticipates 2025 revenues between $420 million and $435 million, with an adjusted EBITDA forecast of $83 million to $91 million, indicating a positive outlook for the year.
The company reported strong growth in Latin America and Asia Pacific regions, and its product lines like On-X and stent grafts showed notable performance despite the challenges. Looking ahead, Artivion expects a rebound in sales growth throughout 2025, with significant contributions from product innovations such as the AMDS device. The company remains focused on overcoming the cybersecurity incident’s impact and achieving its financial targets for the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.